FDA
-
-
-
-
-
-
-
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of
-
-
-
-
-
-
-
Praxis to present ulixacaltamide essential tremor data at AAN 2026
-
-
-
-
-
-
-
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
-
-
-
-
-
-
-
TD Cowen: 'We view yesterday's announcement as highly positive for PRAX'
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $750 (from $250) at Oppenheimer
-
-
-
-
-
-
-
Praxis Precision Medicines Inc. (PRAX) PT Raised to $760 at Guggenheim, 'remains one of our top picks for 2025'
-
-
-
-
-
-
-
Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
-
326,538 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

